# NCT03646123 (NCT03646123)

> Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03646123
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Seagen Inc.
- Conditions: Hodgkin Lymphoma
- Interventions: brentuximab vedotin; doxorubicin; vinblastine; dacarbazine; G-CSF; nivolumab
- Enrollment: 255
- Primary outcome: Febrile Neutropenia (FN) Rate (Part A)
- Primary outcome: Complete Response (CR) Rate at EOT (Parts B and C)

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03646123